These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24210128)

  • 1. Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.
    Kaliberov SA; Kaliberova LN; Hong Lu Z; Preuss MA; Barnes JA; Stockard CR; Grizzle WE; Arbeit JM; Curiel DT
    Virology; 2013 Dec; 447(1-2):312-25. PubMed ID: 24210128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
    Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
    Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.
    Stepanenko AA; Chekhonin VP
    Virus Res; 2018 Sep; 257():40-51. PubMed ID: 30125593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
    Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
    J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic strategy to decrease complement activation with adenoviral therapies.
    Gentile CM; Borovjagin AV; Richter JR; Jani AH; Wu H; Zinn KR; Warram JM
    PLoS One; 2019; 14(4):e0215226. PubMed ID: 31026285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.
    Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH
    J Control Release; 2012 Dec; 164(3):394-402. PubMed ID: 22626939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.
    Alba R; Bradshaw AC; Parker AL; Bhella D; Waddington SN; Nicklin SA; van Rooijen N; Custers J; Goudsmit J; Barouch DH; McVey JH; Baker AH
    Blood; 2009 Jul; 114(5):965-71. PubMed ID: 19429866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.
    Alba R; Bradshaw AC; Coughlan L; Denby L; McDonald RA; Waddington SN; Buckley SM; Greig JA; Parker AL; Miller AM; Wang H; Lieber A; van Rooijen N; McVey JH; Nicklin SA; Baker AH
    Blood; 2010 Oct; 116(15):2656-64. PubMed ID: 20610817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of adenovirus species C hexon to prothrombin and the influence of hexon on vector properties in vitro and in vivo.
    Tian J; Xu Z; Moitra R; Palmer DJ; Ng P; Byrnes AP
    PLoS Pathog; 2022 Sep; 18(9):e1010859. PubMed ID: 36156097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.
    Krutzke L; Prill JM; Engler T; Schmidt CQ; Xu Z; Byrnes AP; Simmet T; Kreppel F
    J Control Release; 2016 Aug; 235():379-392. PubMed ID: 27302248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo.
    Ma J; Duffy MR; Deng L; Dakin RS; Uil T; Custers J; Kelly SM; McVey JH; Nicklin SA; Baker AH
    PLoS Pathog; 2015 Feb; 11(2):e1004673. PubMed ID: 25658827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
    Bradley RR; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
    J Virol; 2012 Jan; 86(1):625-9. PubMed ID: 22072776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
    Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
    J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting.
    Lu ZH; Dmitriev IP; Brough DE; Kashentseva EA; Li J; Curiel DT
    J Virol; 2020 May; 94(10):. PubMed ID: 32102889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
    Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
    J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.
    Bayo-Puxan N; Cascallo M; Gros A; Huch M; Fillat C; Alemany R
    J Gen Virol; 2006 Sep; 87(Pt 9):2487-2495. PubMed ID: 16894186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus hexon modifications influence in vitro properties of pseudotyped human adenovirus type 5 vectors.
    Solanki M; Zhang W; Jing L; Ehrhardt A
    J Gen Virol; 2016 Jan; 97(1):160-168. PubMed ID: 26519158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumvention of immunity to the adenovirus major coat protein hexon.
    Roy S; Shirley PS; McClelland A; Kaleko M
    J Virol; 1998 Aug; 72(8):6875-9. PubMed ID: 9658137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
    Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
    J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.
    Yu D; Jin C; Leja J; Majdalani N; Nilsson B; Eriksson F; Essand M
    J Virol; 2011 Dec; 85(24):13114-23. PubMed ID: 21957304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.